Hormones

Low Libido in Menopause

Creator: Dr Nadira Awal
Published: 2026-01-15

Hormones, relationships and self-image — a whole-person approach to desire.

By Dr Nadira AwalBMS Specialist4 min readMedically reviewed 9 July 2026

Two cups of tea beside soft bedding and warm bedside light

Testosterone can help selected women, but sleep, stress, GSM and relationship dynamics matter just as much. A tailored plan works better than any single fix.

Low libido is one of the most common symptoms women bring to our clinic — and one of the most misunderstood. Desire is not a switch; it is the output of a biological system (oestrogen, testosterone, sleep, thyroid, medication), a psychological system (mood, self-image, past experience, stress) and a relational system (safety, novelty, resentment, communication). Treatment that ignores any of those layers rarely works. Fortunately, when all three are addressed together, most women see meaningful improvement within 3–6 months.

Understanding the biology

Falling oestrogen thins vulval and vaginal tissues, reduces natural lubrication and blunts genital blood flow — sex becomes uncomfortable, which naturally lowers anticipatory desire.
Testosterone falls gradually from the mid-30s and steeply after ovarian ageing or surgical menopause; it drives spontaneous desire, arousal intensity and orgasm capacity.
Rising SHBG (sex hormone binding globulin) — often from oral oestrogen or the combined pill — mops up free testosterone, further lowering libido.
Chronic sleep deprivation, thyroid disease, iron deficiency and elevated prolactin all suppress desire independently.
Common medications that dampen libido: SSRIs and SNRIs (fluoxetine, sertraline, citalopram, venlafaxine), beta-blockers, some antihistamines, opioids and the combined pill.

The medical levers

First: optimise systemic oestrogen. Most women need transdermal oestrogen at a dose that fully controls flushes, sleep and mood before libido responds.
Second: treat genitourinary syndrome of menopause. Vaginal oestrogen is not optional for the majority of postmenopausal women with low desire — dry, painful tissues make desire biologically implausible.
Third: consider testosterone. In the UK, testosterone is prescribed off-licence per BMS guidance for postmenopausal HSDD (hypoactive sexual desire disorder) after 3–6 months of stable oestrogen. Usual product: AndroFeme cream, 0.5 ml daily (5 mg).
Baseline total testosterone and SHBG are checked before starting; a repeat at 3 months confirms levels are in the female physiological range (not male range).
Fair trial: 3–6 months. About half of women see clear benefit; the other half stop without concern.
Review antidepressants: switching from an SSRI to bupropion, mirtazapine, agomelatine or vortioxetine often restores desire — always with the prescriber.

Couple laughing on a sofa at home, calm and connected — Desire in long-term relationships is usually responsive, not spontaneous — the biology is only one of three levers.

The life levers that unlock the medical ones

Sleep is the single most underrated libido intervention. Chronic short sleep drops testosterone by 10–15% in weeks.
Alcohol reduction — even to 3–4 units a week — often lifts desire within a month.
Strength training twice weekly raises testosterone, improves body image and boosts confidence — all libido-relevant.
Stress load: chronic elevated cortisol suppresses gonadotropins. Untreated anxiety needs its own plan.
Untreated low mood must be addressed in parallel — no hormone will bypass depression.

The relational levers

Desire in long-term relationships is mostly responsive, not spontaneous — you feel like sex once things start, not before. This is normal and does not indicate a problem.
Non-sexual affection (hugs, hand-holding, protected time together) rebuilds the emotional bandwidth for desire.
Honest conversation about what has changed physically and emotionally — outside the bedroom, not during sex — reduces the anticipatory anxiety that shuts desire down.
Novelty matters: new environments, weekends away, changing the timing of intimacy from ‘end of day exhausted’ to ‘morning’ or ‘afternoon’.
Unresolved resentment is the most common invisible libido blocker. Couples work — even 4–6 sessions — often unlocks more than any hormone.

AndroFeme testosterone cream and metered applicator — Testosterone is prescribed off-licence in the UK for postmenopausal HSDD after 3–6 months of stable oestrogen — a fair trial is 3–6 months.

When to consider psychosexual therapy

Persistent low desire despite optimised HRT and testosterone.
History of sexual pain, trauma or a relationship rupture.
Loss of arousal or orgasm rather than desire alone.
Body-image distress after weight change, surgery or cancer treatment.
COSRT (cosrt.org.uk) and Relate list accredited UK therapists; typical courses are 6–12 sessions.

What realistic outcomes look like

Full oestrogen + vaginal oestrogen: sex becomes possible and comfortable again for most women within 8–12 weeks.
Adding testosterone: about 50% of women notice clearer desire, better arousal and stronger orgasms by 3–6 months.
Combined with lifestyle and relational work: 70–80% of women report a satisfactory sex life within 6–12 months.
‘Back to my 20s’ is not the goal — a comfortable, connected, satisfying sex life is very achievable.

Red flags that need review before assuming ‘just menopause’

New pain with sex that doesn’t respond to vaginal oestrogen — screen for lichen sclerosus, endometriosis, pelvic floor dysfunction.
Bleeding after sex in a postmenopausal woman — same-week medical review.
Loss of desire with unexplained fatigue, weight change or milk discharge — thyroid and prolactin bloods.
Sudden change with new relationship distress or trauma — psychological support first.

Key takeaway

Low libido in menopause is rarely fixed by one thing. Optimise oestrogen, treat GSM, trial testosterone for 3–6 months if appropriate, protect sleep, moderate alcohol, and address the relational and psychological layers in parallel — most women see meaningful change within six months.

How Dr Awal approaches this in clinic

Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.

A detailed 60 minute first appointment — no rushed 10-minute slots.
Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
Body-identical HRT considered first-line where appropriate.
Shared-care letters sent to your NHS GP so treatment can continue affordably.
Follow-up at 3 months to fine-tune your regimen and address side effects.
Ongoing annual reviews so your plan evolves with you.

Common questions we hear about this

Do I need to be at a certain age to be seen?

No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.

Will my GP continue the prescription?

In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.

What if I've tried HRT before and it didn't suit me?

Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.

How long will I need to stay on treatment?

There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.

Where do you see patients?

All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.

About the author

Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.

Sources & further reading

General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.

Talk it through